Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm.

Abstract

It is increasingly recognized that the bladder is the originator of storage lower urinary tract symptoms, including overactive bladder in men. As these symptoms are most bothersome for patients, there has been an increasing interest in the evaluation of drug treatment to better target the bladder. Consequently, several new drug classes have been introduced to the therapeutic armamentarium. Antimuscarinics, which were previously avoided due to the concern regarding urinary retention, are now used in routine practice; however, their use is still hampered by discontinuation due to side effects.

• Authors: Nadir I Osman, Reem Aldamanhori, Altaf Mangera, Christopher R Chapple
• Journal: The Urologic clinics of North America (Urol Clin North Am) Vol. 43 Issue 3 Pg. 337-49 (Aug 2016) ISSN: 1558-318X [Electronic] United States
• PMID: 27476126 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 Elsevier Inc. All rights reserved.

Chemical References

• Adrenergic beta-3 Receptor Agonists
• Muscarinic Antagonists
• Phosphodiesterase Inhibitors

Topics

• Adrenergic beta-3 Receptor Agonists (therapeutic use)
• Drug Therapy, Combination
• Humans
• Lower Urinary Tract Symptoms (drug therapy, etiology, physiopathology)
• Male
• Muscarinic Antagonists (therapeutic use)
• Phosphodiesterase Inhibitors (therapeutic use)
• Prostatic Hyperplasia (complications, drug therapy)
• Urodynamics (drug effects)